Safety of clopidogrel in hip fracture surgery

Molly A. Feely, Tad M. Mabry, Christine M. Lohse, Stephen A. Sems, Karen F. Mauck

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: To compare postoperative outcomes of hip fracture surgery in patients who were and were not taking clopidogrel at the time of surgery. Patients and Methods: Using the Rochester Epidemiology Project database, we performed a populationbased, retrospective cohort study comparing patients who were and were not taking clopidogrel at the time of hip fracture surgery between January 1, 1996, and June 30, 2010. Primary outcomes were perioperative bleeding and mortality. Secondary outcomes were perioperative thrombotic events. Results: During the study period, 40 residents of Olmsted County, Minnesota (median age, 83 years), who were taking clopidogrel underwent hip fracture repair. These 40 patients were matched 2:1 with 80 control patients (median age, 84 years). The groups were similar in age, sex, American Society of Anesthesiologists score, type of surgical procedure, and use of deep venous thrombosis prophylaxis. The mean time from admission to surgery was less than 36 hours for each cohort. Perioperative bleeding complications and mortality were not significantly different between patients who were and were not taking clopidogrel at the time of hip fracture surgery. Combined bleeding outcome criteria was met in 48% of the clopidogrel cohort and 45% of the control cohort (relative risk, 1.06; 95% CI, 0.70-1.58; P=.80). One-year mortality was 28% in the clopidogrel cohort and 29% in the control cohort (hazard ratio, 1.33; 95% CI, 0.84-2.12; P=.23). Conclusion: Although the small sample size precludes making a definitive conclusion, we found no evidence that prompt surgical treatment of hip fracture in patients taking clopidogrel compromises perioperative outcomes.

Original languageEnglish (US)
Pages (from-to)149-156
Number of pages8
JournalMayo Clinic Proceedings
Volume88
Issue number2
DOIs
StatePublished - 2013

Fingerprint

clopidogrel
Hip Fractures
Safety
Hemorrhage
Mortality
Safety Management
Venous Thrombosis
Sample Size
Epidemiology
Cohort Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Feely, M. A., Mabry, T. M., Lohse, C. M., Sems, S. A., & Mauck, K. F. (2013). Safety of clopidogrel in hip fracture surgery. Mayo Clinic Proceedings, 88(2), 149-156. https://doi.org/10.1016/j.mayocp.2012.11.007

Safety of clopidogrel in hip fracture surgery. / Feely, Molly A.; Mabry, Tad M.; Lohse, Christine M.; Sems, Stephen A.; Mauck, Karen F.

In: Mayo Clinic Proceedings, Vol. 88, No. 2, 2013, p. 149-156.

Research output: Contribution to journalArticle

Feely, MA, Mabry, TM, Lohse, CM, Sems, SA & Mauck, KF 2013, 'Safety of clopidogrel in hip fracture surgery', Mayo Clinic Proceedings, vol. 88, no. 2, pp. 149-156. https://doi.org/10.1016/j.mayocp.2012.11.007
Feely, Molly A. ; Mabry, Tad M. ; Lohse, Christine M. ; Sems, Stephen A. ; Mauck, Karen F. / Safety of clopidogrel in hip fracture surgery. In: Mayo Clinic Proceedings. 2013 ; Vol. 88, No. 2. pp. 149-156.
@article{75354ef5703b40759cacd54ffc6baaa6,
title = "Safety of clopidogrel in hip fracture surgery",
abstract = "Objective: To compare postoperative outcomes of hip fracture surgery in patients who were and were not taking clopidogrel at the time of surgery. Patients and Methods: Using the Rochester Epidemiology Project database, we performed a populationbased, retrospective cohort study comparing patients who were and were not taking clopidogrel at the time of hip fracture surgery between January 1, 1996, and June 30, 2010. Primary outcomes were perioperative bleeding and mortality. Secondary outcomes were perioperative thrombotic events. Results: During the study period, 40 residents of Olmsted County, Minnesota (median age, 83 years), who were taking clopidogrel underwent hip fracture repair. These 40 patients were matched 2:1 with 80 control patients (median age, 84 years). The groups were similar in age, sex, American Society of Anesthesiologists score, type of surgical procedure, and use of deep venous thrombosis prophylaxis. The mean time from admission to surgery was less than 36 hours for each cohort. Perioperative bleeding complications and mortality were not significantly different between patients who were and were not taking clopidogrel at the time of hip fracture surgery. Combined bleeding outcome criteria was met in 48{\%} of the clopidogrel cohort and 45{\%} of the control cohort (relative risk, 1.06; 95{\%} CI, 0.70-1.58; P=.80). One-year mortality was 28{\%} in the clopidogrel cohort and 29{\%} in the control cohort (hazard ratio, 1.33; 95{\%} CI, 0.84-2.12; P=.23). Conclusion: Although the small sample size precludes making a definitive conclusion, we found no evidence that prompt surgical treatment of hip fracture in patients taking clopidogrel compromises perioperative outcomes.",
author = "Feely, {Molly A.} and Mabry, {Tad M.} and Lohse, {Christine M.} and Sems, {Stephen A.} and Mauck, {Karen F.}",
year = "2013",
doi = "10.1016/j.mayocp.2012.11.007",
language = "English (US)",
volume = "88",
pages = "149--156",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Safety of clopidogrel in hip fracture surgery

AU - Feely, Molly A.

AU - Mabry, Tad M.

AU - Lohse, Christine M.

AU - Sems, Stephen A.

AU - Mauck, Karen F.

PY - 2013

Y1 - 2013

N2 - Objective: To compare postoperative outcomes of hip fracture surgery in patients who were and were not taking clopidogrel at the time of surgery. Patients and Methods: Using the Rochester Epidemiology Project database, we performed a populationbased, retrospective cohort study comparing patients who were and were not taking clopidogrel at the time of hip fracture surgery between January 1, 1996, and June 30, 2010. Primary outcomes were perioperative bleeding and mortality. Secondary outcomes were perioperative thrombotic events. Results: During the study period, 40 residents of Olmsted County, Minnesota (median age, 83 years), who were taking clopidogrel underwent hip fracture repair. These 40 patients were matched 2:1 with 80 control patients (median age, 84 years). The groups were similar in age, sex, American Society of Anesthesiologists score, type of surgical procedure, and use of deep venous thrombosis prophylaxis. The mean time from admission to surgery was less than 36 hours for each cohort. Perioperative bleeding complications and mortality were not significantly different between patients who were and were not taking clopidogrel at the time of hip fracture surgery. Combined bleeding outcome criteria was met in 48% of the clopidogrel cohort and 45% of the control cohort (relative risk, 1.06; 95% CI, 0.70-1.58; P=.80). One-year mortality was 28% in the clopidogrel cohort and 29% in the control cohort (hazard ratio, 1.33; 95% CI, 0.84-2.12; P=.23). Conclusion: Although the small sample size precludes making a definitive conclusion, we found no evidence that prompt surgical treatment of hip fracture in patients taking clopidogrel compromises perioperative outcomes.

AB - Objective: To compare postoperative outcomes of hip fracture surgery in patients who were and were not taking clopidogrel at the time of surgery. Patients and Methods: Using the Rochester Epidemiology Project database, we performed a populationbased, retrospective cohort study comparing patients who were and were not taking clopidogrel at the time of hip fracture surgery between January 1, 1996, and June 30, 2010. Primary outcomes were perioperative bleeding and mortality. Secondary outcomes were perioperative thrombotic events. Results: During the study period, 40 residents of Olmsted County, Minnesota (median age, 83 years), who were taking clopidogrel underwent hip fracture repair. These 40 patients were matched 2:1 with 80 control patients (median age, 84 years). The groups were similar in age, sex, American Society of Anesthesiologists score, type of surgical procedure, and use of deep venous thrombosis prophylaxis. The mean time from admission to surgery was less than 36 hours for each cohort. Perioperative bleeding complications and mortality were not significantly different between patients who were and were not taking clopidogrel at the time of hip fracture surgery. Combined bleeding outcome criteria was met in 48% of the clopidogrel cohort and 45% of the control cohort (relative risk, 1.06; 95% CI, 0.70-1.58; P=.80). One-year mortality was 28% in the clopidogrel cohort and 29% in the control cohort (hazard ratio, 1.33; 95% CI, 0.84-2.12; P=.23). Conclusion: Although the small sample size precludes making a definitive conclusion, we found no evidence that prompt surgical treatment of hip fracture in patients taking clopidogrel compromises perioperative outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84876555896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876555896&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2012.11.007

DO - 10.1016/j.mayocp.2012.11.007

M3 - Article

C2 - 23374618

AN - SCOPUS:84876555896

VL - 88

SP - 149

EP - 156

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -